IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Handelsbanken Fonder AB

Handelsbanken Fonder AB decreased its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 28.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 188,209 shares of the medical research company's stock after selling 75,454 shares during the period. Handelsbanken Fonder AB owned approximately 0.11% of IQVIA worth $33,181,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Vanguard Group Inc. raised its position in IQVIA by 0.5% during the fourth quarter. Vanguard Group Inc. now owns 20,131,734 shares of the medical research company's stock worth $3,956,087,000 after acquiring an additional 105,504 shares during the last quarter. Canada Pension Plan Investment Board raised its position in shares of IQVIA by 20.0% in the fourth quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company's stock valued at $841,461,000 after buying an additional 712,958 shares during the last quarter. Geode Capital Management LLC raised its position in shares of IQVIA by 1.9% in the fourth quarter. Geode Capital Management LLC now owns 4,175,524 shares of the medical research company's stock valued at $818,315,000 after buying an additional 77,981 shares during the last quarter. Invesco Ltd. raised its position in shares of IQVIA by 53.4% in the fourth quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company's stock valued at $509,012,000 after buying an additional 902,226 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. raised its position in shares of IQVIA by 2.5% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,438,726 shares of the medical research company's stock valued at $481,380,000 after buying an additional 59,426 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on IQV. HSBC lowered shares of IQVIA from a "buy" rating to a "hold" rating and cut their price objective for the company from $260.00 to $160.00 in a research report on Friday, April 25th. Citigroup reissued a "neutral" rating on shares of IQVIA in a research report on Thursday, May 22nd. Wall Street Zen lowered shares of IQVIA from a "buy" rating to a "hold" rating in a research report on Wednesday, March 12th. Barclays cut their price objective on shares of IQVIA from $170.00 to $165.00 and set an "equal weight" rating for the company in a research report on Wednesday, May 7th. Finally, UBS Group lowered their target price on shares of IQVIA from $255.00 to $185.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Eight research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $226.32.

IQVIA Stock Down 1.6%

Shares of NYSE IQV traded down $2.48 during trading on Friday, reaching $156.65. 1,473,864 shares of the stock were exchanged, compared to its average volume of 1,619,178. The business's 50-day moving average price is $147.59 and its 200 day moving average price is $177.68. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $252.88. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The company has a market capitalization of $27.10 billion, a price-to-earnings ratio of 20.89, a price-to-earnings-growth ratio of 1.99 and a beta of 1.28.

IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, topping analysts' consensus estimates of $2.63 by $0.07. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The business had revenue of $3.83 billion for the quarter, compared to analysts' expectations of $3.77 billion. During the same period in the previous year, the company posted $2.54 earnings per share. The business's revenue for the quarter was up 2.5% compared to the same quarter last year. As a group, equities analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.